Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-α-expressing cells
S Verstovsek, FJ Giles, A Quintás-Cardama… - Leukemia research, 2006 - Elsevier
Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized
by tissue involvement and organ dysfunction due to abnormal eosinophil proliferation. In a
subset of patients, this is caused by the FIP1L1-PDGFR-α fusion tyrosine kinase. Cumulative
evidence indicates that the Bcr-Abl tyrosine kinase inhibitor imatinib mesylate (Gleevec) is
active for the treatment of patients with HES, particularly those expressing the FIP1L1-
PDGFR-α oncoprotein. The novel tyrosine kinase inhibitor AMN107 was initially developed …
by tissue involvement and organ dysfunction due to abnormal eosinophil proliferation. In a
subset of patients, this is caused by the FIP1L1-PDGFR-α fusion tyrosine kinase. Cumulative
evidence indicates that the Bcr-Abl tyrosine kinase inhibitor imatinib mesylate (Gleevec) is
active for the treatment of patients with HES, particularly those expressing the FIP1L1-
PDGFR-α oncoprotein. The novel tyrosine kinase inhibitor AMN107 was initially developed …
